Mitsubishi Gas Chemical Company (MGC), a chemical and life science technology company, is cooperating with Alerje. As an emergency medicine and food allergy management company, we are revolutionizing allergy diagnosis and treatment worldwide.
The goal of this alliance is to create a comprehensive, personalized allergy treatment strategy that improves patients’ quality of life and treatment outcomes.
Key elements of the partnership include a joint effort by both companies to bring a cutting-edge allergy diagnostics platform to the U.S. market and integrate food allergy technologies aimed at providing a holistic view of personalized allergy treatment.
This partnership is in line with MGC’s long-term plans to target the healthcare and food sectors.
“This partnership with MGC represents an important milestone in our mission to improve the lives of millions of people suffering from allergies,” Javier Evelyn, Alerje’s founder and CEO, said in a statement.
“By joining forces, we are poised to make unprecedented advances in allergy diagnosis and management.”
The two companies claim that their joint research aims to transform the lives of people with food allergies by combining better testing with innovative treatments.
“Together, we aim to set a new standard in allergy management and leverage our combined technologies and expertise to address unmet needs in the U.S. and Japanese markets,” Yoshinori Isahaya, MGC’s director and executive vice president, said in a statement.
The bigger trend
Other agencies involved in food allergies include: In 2017, Harvard Medical School created a point-of-use food allergy detector that clips to a keychain and can be used to test for food allergens in minutes. The device is designed to detect major allergens at sensitivities well below regulatory limits.
In 2016, 6SensorLabs, a smartphone-based allergen testing company, rebranded as Nima and raised $9.2 million to build a range of food testing devices. Nima used the funds to market its food sensors for peanuts and dairy products.
In 2023 Alerje received a Phase II grant from the National Science Foundation’s Small Business Innovation Research program. The $1 million grant will be used to expand the company’s AI digital platform capacity and scale up manufacturing of its epinephrine autoinjector solution.
